Halozyme Therapeutics (HALO) Share-based Compensation (2010 - 2026)

Halozyme Therapeutics (HALO) has 17 years of Share-based Compensation data on file, last reported at $170000.0 in Q1 2026.

• On a quarterly basis, Share-based Compensation fell 98.41% year-over-year to $170000.0 in Q1 2026; TTM through Mar 2026 was $41.1 million, a 23.35% decrease from a year earlier, with the FY2025 full-year figure at $51.6 million, up 18.85% from the prior year.
• Share-based Compensation for Q1 2026 stood at $170000.0, down from $51.1 million in the prior quarter.
• Over the last five years, Share-based Compensation for HALO reached as high as $51.1 million in Q4 2025 and fell as low as -$9.9 million in Q2 2025.
• Historically, Share-based Compensation has averaged $7.8 million across 5 years, with a median of $753000.0 in 2022.
• Across the five-year window, Share-based Compensation soared 17404.02% in 2024 and plunged 1117.5% in 2025, its largest moves.
• Year by year, Share-based Compensation stood at $33.5 million in 2022, then plunged by 95.93% to $1.4 million in 2023, then jumped by 742.17% to $11.5 million in 2024, then jumped by 346.17% to $51.1 million in 2025, then slumped by 99.67% to $170000.0 in 2026.
• Per Business Quant data, the three most recent Share-based Compensation figures were $170000.0 in Q1 2026, $51.1 million in Q4 2025, and -$307000.0 in Q3 2025.